drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Antibody–drug conjugate: humanized anti-HER2 IgG1 (trastuzumab) linked to a topoisomerase I inhibitor payload (DXd); binds HER2, is internalized, releases DXd to inhibit topo I causing DNA damage/apoptosis; can mediate ADCC and has a bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
trastuzumab deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 IgG1 antibody–drug conjugate (trastuzumab linked via a cleavable linker to the topoisomerase I inhibitor DXd). Binds HER2 on tumor cells, is internalized, and releases DXd to inhibit topoisomerase I, causing DNA damage and apoptosis; the Fc can mediate ADCC, and the membrane-permeable payload enables a bystander killing effect.
drug_name
Trastuzumab deruxtecan (T-DXd, Enhertu)
nct_id_drug_ref
NCT05945732